Advertisement
Correspondence| Volume 62, ISSUE 6, P703-704, September 15, 2007

Reply

  • Author Footnotes
    1 Full-time employee at Bristol-Myers Squibb GmbH & Co. KGaA, Munich, Germany, as Medical Director Neuroscience and Immunology. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Sieglinde Modell
    Footnotes
    1 Full-time employee at Bristol-Myers Squibb GmbH & Co. KGaA, Munich, Germany, as Medical Director Neuroscience and Immunology. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Search for articles by this author
  • Author Footnotes
    2 Head of the research group Molecular Psychology at the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Marcus Ising
    Footnotes
    2 Head of the research group Molecular Psychology at the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Search for articles by this author
  • Author Footnotes
    3 Director of the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: Bristol-Myers Squibb. Consultant: Corcept Therapeutics. Speakers bureau: none. Major stockshare holder: Affectis Pharmaceuticals. Other: Editor in Chief Journal of Psychiatric Research.
    Florian Holsboer
    Footnotes
    3 Director of the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: Bristol-Myers Squibb. Consultant: Corcept Therapeutics. Speakers bureau: none. Major stockshare holder: Affectis Pharmaceuticals. Other: Editor in Chief Journal of Psychiatric Research.
    Search for articles by this author
  • Author Footnotes
    4 Head of the Sleep Disorders Center at the Angermühle Hospital, Deggendorf, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Christoph J. Lauer
    Footnotes
    4 Head of the Sleep Disorders Center at the Angermühle Hospital, Deggendorf, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    Search for articles by this author
  • Author Footnotes
    1 Full-time employee at Bristol-Myers Squibb GmbH & Co. KGaA, Munich, Germany, as Medical Director Neuroscience and Immunology. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    2 Head of the research group Molecular Psychology at the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
    3 Director of the Max-Planck-Institute of Psychiatry, Munich, Germany. Grant/Research support: Bristol-Myers Squibb. Consultant: Corcept Therapeutics. Speakers bureau: none. Major stockshare holder: Affectis Pharmaceuticals. Other: Editor in Chief Journal of Psychiatric Research.
    4 Head of the Sleep Disorders Center at the Angermühle Hospital, Deggendorf, Germany. Grant/Research support: none. Consultant: none. Speakers bureau: none. Major stockshare holder: none. Other: none.
      We appreciate the opportunity to reply to the arguments raised by Dr. Carroll about the conclusions of our study published in Biological Psychiatry (
      • Modell S.
      • Ising M.
      • Holsboer F.
      • Lauer C.J.
      The Munich Vulnerability Study on Affective Disorders: Premorbid polysomnographic profile of affected high-risk probands.
      ). We demonstrated in this study that elevated rapid eye movement (REM) density can be observed not only in patients with depression but also in high-risk probands, that is, in healthy first-degree relatives of depressed patients, who developed a psychiatric disorder during follow-up. These high-risk probands had higher REM density scores than matched control subjects without a personal or family history of psychiatric disorders; affected high-risk probands, however, did not differ from other high-risk probands who did not develop a psychiatric disorder during follow-up.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Modell S.
        • Ising M.
        • Holsboer F.
        • Lauer C.J.
        The Munich Vulnerability Study on Affective Disorders: Premorbid polysomnographic profile of affected high-risk probands.
        Biol Psychiatry. 2005; 58: 694-699
        • Gottesman I.I.
        • Gould T.D.
        The endophenotype concept in psychiatry: Etymology and strategic intentions.
        Am J Psychiatry. 2003; 160: 636-645
        • Hudson J.I.
        • Pope Jr., H.G.
        Affective spectrum disorder: Does antidepressant response identify a family of disorders with a common pathophysiology?.
        Am J Psychiatry. 1990; 147: 552-564
        • Jacobi F.
        • Wittchen H.U.
        • Holting C.
        • Hofler M.
        • Pfister H.
        • Muller N.
        • et al.
        Prevalence, co-morbidity and correlates of mental disorders in the general population: Results from the German Health Interview and Examination Survey (GHS).
        Psychol Med. 2004; 34: 597-611
        • Ising M.
        • Adena S.M.
        • Pfennig A.
        • Binder E.
        • Kern N.
        • Huber J.
        • et al.
        Munich Vulnerability Study—Familial vulnerability for affective disorders: search for endophenotypes.
        Pharmacopsychiatry. 2003; 36: 237

      Linked Article